News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
813,862 Results
Type
Article (74134)
Company Profile (643)
Press Release (739085)
Multimedia
Podcasts (122)
Webinars (14)
Section
Business (226461)
Career Advice (3715)
Deals (39166)
Drug Delivery (129)
Drug Development (89002)
Employer Resources (198)
FDA (17798)
Job Trends (17078)
News (386080)
Policy (38635)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (6)
2025 BioForest Digital (6)
2025 Lone Star Bio Digital (9)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (92)
Alliances (55820)
ALS (99)
Alzheimer's disease (1498)
Antibody-drug conjugate (ADC) (156)
Approvals (17765)
Artificial intelligence (291)
Autoimmune disease (28)
Automation (16)
Bankruptcy (402)
Best Places to Work (12632)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (439)
Bladder cancer (84)
Brain cancer (31)
Breast cancer (296)
Cancer (2389)
Cardiovascular disease (202)
Career advice (3163)
Career pathing (34)
CAR-T (167)
Cell therapy (466)
Cervical cancer (21)
Clinical research (71876)
Collaboration (899)
Compensation (541)
Complete response letters (30)
COVID-19 (2862)
CRISPR (46)
C-suite (257)
Cystic fibrosis (107)
Data (2218)
Decentralized trials (2)
Denatured (40)
Depression (53)
Diabetes (291)
Diagnostics (6910)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (125)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (93199)
Editorial (43)
Employer branding (25)
Employer resources (167)
Events (128466)
Executive appointments (764)
FDA (19090)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (803)
Gene editing (116)
Generative AI (27)
Gene therapy (345)
GLP-1 (845)
Government (5103)
Grass and pollen (6)
Guidances (53)
Healthcare (20868)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (143)
Indications (30)
Infectious disease (3022)
Inflammatory bowel disease (151)
Inflation Reduction Act (11)
Influenza (56)
Intellectual property (100)
Interviews (726)
IPO (17708)
IRA (51)
Job creations (4937)
Job search strategy (2589)
Kidney cancer (11)
Labor market (42)
Layoffs (549)
Leadership (22)
Legal (9886)
Liver cancer (80)
Lung cancer (342)
Lymphoma (155)
Machine learning (6)
Management (65)
Manufacturing (336)
MASH (73)
Medical device (14606)
Medtech (14611)
Mergers & acquisitions (21985)
Metabolic disorders (774)
Multiple sclerosis (84)
NASH (23)
Neurodegenerative disease (109)
Neuropsychiatric disorders (34)
Neuroscience (2083)
NextGen: Class of 2025 (7634)
Non-profit (5077)
Northern California (2696)
Now hiring (40)
Obesity (419)
Opinion (274)
Ovarian cancer (76)
Pain (95)
Pancreatic cancer (84)
Parkinson's disease (158)
Partnered (22)
Patents (248)
Patient recruitment (110)
Peanut (51)
People (63768)
Pharmaceutical (132)
Pharmacy benefit managers (21)
Phase I (22205)
Phase II (31351)
Phase III (23657)
Pipeline (1207)
Policy (168)
Postmarket research (3239)
Preclinical (9768)
Press Release (72)
Prostate cancer (111)
Psychedelics (38)
Radiopharmaceuticals (268)
Rare diseases (424)
Real estate (7112)
Recruiting (75)
Regulatory (25937)
Reports (57)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (4)
RNA editing (4)
RSV (50)
Schizophrenia (78)
Series A (142)
Series B (90)
Service/supplier (26)
Sickle cell disease (58)
Southern California (2339)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4185)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (39)
The Weekly (80)
United States (24193)
Vaccines (804)
Venture capitalists (44)
Weight loss (301)
Women's health (37)
Worklife (19)
Date
Today (218)
Last 7 days (864)
Last 30 days (2693)
Last 365 days (35489)
2025 (10913)
2024 (37887)
2023 (42567)
2022 (53926)
2021 (58722)
2020 (57663)
2019 (51302)
2018 (39083)
2017 (36786)
2016 (37675)
2015 (43661)
2014 (38254)
2013 (34183)
2012 (36131)
2011 (36206)
2010 (35533)
Location
Africa (1186)
Alabama (59)
Alaska (7)
Arizona (243)
Arkansas (14)
Asia (48494)
Australia (8326)
California (6290)
Canada (2028)
China (551)
Colorado (281)
Connecticut (296)
Delaware (151)
Europe (109469)
Florida (917)
Georgia (217)
Hawaii (1)
Idaho (63)
Illinois (601)
India (30)
Indiana (330)
Iowa (12)
Japan (163)
Kansas (108)
Kentucky (27)
Louisiana (14)
Maine (70)
Maryland (947)
Massachusetts (4847)
Michigan (240)
Minnesota (414)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (68)
New Jersey (1783)
New Mexico (31)
New York (1784)
North Carolina (1108)
North Dakota (8)
Northern California (2696)
Ohio (214)
Oklahoma (15)
Oregon (46)
Pennsylvania (1390)
Puerto Rico (12)
Rhode Island (35)
South America (1560)
South Carolina (23)
South Dakota (1)
Southern California (2339)
Tennessee (104)
Texas (934)
Utah (188)
Virginia (166)
Washington D.C. (69)
Washington State (593)
West Virginia (3)
Wisconsin (64)
813,862 Results for "zenyaku kogyo co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
epitoMAP Inc. and Animal Allergy Clinical Laboratories Inc. entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. on November 10, 2023.
November 17, 2023
·
2 min read
Business
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd., to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis, dupilumab and lebrikizumab.
May 2, 2024
·
7 min read
Business
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
ASLAN Pharmaceuticals and Zenyaku Kogyo Co., Ltd. (“Zenyaku”), a subsidiary of privately held Zenyaku Holdings Co., Ltd. (“Zenyaku Holdings”), today announced a strategic licensing agreement granting Zenyaku exclusive rights to develop and commercialize eblasakimab in atopic dermatitis (AD) and all other indications in Japan.
June 22, 2023
·
8 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Press Releases
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments
April 28, 2025
·
10 min read
1 of 81,387
Next
